These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
504 related articles for article (PubMed ID: 2540776)
21. Characterization of the receptor for tumor necrosis factor (TNF) and lymphotoxin (LT) on human T lymphocytes. TNF and LT differ in their receptor binding properties and the induction of MHC class I proteins on a human CD4+ T cell hybridoma. Andrews JS; Berger AE; Ware CF J Immunol; 1990 Apr; 144(7):2582-91. PubMed ID: 1969453 [TBL] [Abstract][Full Text] [Related]
22. Multiple sclerosis: expression of molecules of the tumor necrosis factor ligand and receptor families in relationship to the demyelinated plaque. Raine CS; Bonetti B; Cannella B Rev Neurol (Paris); 1998 Sep; 154(8-9):577-85. PubMed ID: 9809372 [TBL] [Abstract][Full Text] [Related]
23. Role of TNF ligand and receptor family in the lymphoid organogenesis defined by gene targeting. Matsumoto M J Med Invest; 1999 Aug; 46(3-4):141-50. PubMed ID: 10687308 [TBL] [Abstract][Full Text] [Related]
24. [Biochemical characterization and metabolic effects of tumor necrosis factor]. Martins e Silva J Acta Med Port; 1991 Dec; 4 Suppl 1():20S-27S. PubMed ID: 1805528 [TBL] [Abstract][Full Text] [Related]
31. Down-modulation of cell surface expression of p80 form of the tumor necrosis factor receptor by human immunodeficiency virus-1 tat gene. Pocsik E; Higuchi M; Aggarwal BB Lymphokine Cytokine Res; 1992 Dec; 11(6):317-25. PubMed ID: 1335762 [TBL] [Abstract][Full Text] [Related]
32. Blocking factors (soluble membrane receptors) for tumor necrosis factor and lymphotoxin detected in ascites and released in short-term cultures obtained from ascites and solid tumors in women with gynecologic malignancy. Grosen EA; Yamamoto RS; Ioli G; Ininns EK; Gatanaga M; Gatanaga T; DiSaia PJ; Berman M; Manetta A; Granger GA Lymphokine Cytokine Res; 1992 Dec; 11(6):347-53. PubMed ID: 1335764 [TBL] [Abstract][Full Text] [Related]
34. The possible role of tumor necrosis factor (TNF) and its natural inhibitors, the soluble-TNF receptors, in autoimmune diseases. Aderka D; Engelmann H; Wysenbeek AJ; Levo Y Isr J Med Sci; 1992 Feb; 28(2):126-30. PubMed ID: 1313788 [No Abstract] [Full Text] [Related]
35. Independent protective effects for tumor necrosis factor and lymphotoxin alpha in the host response to Listeria monocytogenes infection. Roach DR; Briscoe H; Saunders BM; Britton WJ Infect Immun; 2005 Aug; 73(8):4787-92. PubMed ID: 16040991 [TBL] [Abstract][Full Text] [Related]
36. Tumor necrosis factor (TNF) receptor expression in T lymphocytes. Differential regulation of the type I TNF receptor during activation of resting and effector T cells. Ware CF; Crowe PD; Vanarsdale TL; Andrews JL; Grayson MH; Jerzy R; Smith CA; Goodwin RG J Immunol; 1991 Dec; 147(12):4229-38. PubMed ID: 1661312 [TBL] [Abstract][Full Text] [Related]
37. The TNF receptor in TNF-mediated cytotoxicity. Kull FC Nat Immun Cell Growth Regul; 1988; 7(5-6):254-65. PubMed ID: 2851740 [TBL] [Abstract][Full Text] [Related]
38. Tumour necrosis factor/cachectin: biology and relevance to disease. Das UN J Assoc Physicians India; 1991 Feb; 39(2):201-4. PubMed ID: 1885487 [TBL] [Abstract][Full Text] [Related]
39. [Tumor necrosis factor and lymphotoxin: molecular genetics, regulation and physiological role]. Nedospasov SA Genetika; 2003 Feb; 39(2):207-14. PubMed ID: 12669416 [TBL] [Abstract][Full Text] [Related]
40. Lymphotoxin acts as an autocrine growth factor for Epstein-Barr virus-transformed B cells and differentiated Burkitt lymphoma cell lines. Gibbons DL; Rowe M; Cope AP; Feldmann M; Brennan FM Eur J Immunol; 1994 Aug; 24(8):1879-85. PubMed ID: 8056047 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]